NGM Biopharmaceuticals Inc (DELISTED) (NGM:DL)
1.54
0.00 (0.00%)
USD |
NASDAQ |
Apr 05, 16:00
NGM Biopharmaceuticals Cash from Investing (Quarterly): 27.19M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 27.19M |
| September 30, 2023 | 26.87M |
| June 30, 2023 | 24.58M |
| March 31, 2023 | 35.64M |
| December 31, 2022 | 1.688M |
| September 30, 2022 | 35.45M |
| June 30, 2022 | -15.97M |
| March 31, 2022 | -6.853M |
| December 31, 2021 | 21.93M |
| September 30, 2021 | 52.30M |
| June 30, 2021 | -28.72M |
| March 31, 2021 | -117.16M |
| Date | Value |
|---|---|
| December 31, 2020 | -114.53M |
| September 30, 2020 | 28.54M |
| June 30, 2020 | 8.119M |
| March 31, 2020 | 26.87M |
| December 31, 2019 | -46.39M |
| September 30, 2019 | 43.62M |
| June 30, 2019 | 49.00M |
| March 31, 2019 | 2.493M |
| December 31, 2018 | 3.482M |
| September 30, 2018 | 13.22M |
| June 30, 2018 | -8.552M |
| March 31, 2018 | 30.58M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-117.16M
Minimum
Mar 2021
52.30M
Maximum
Sep 2021
2.747M
Average
24.58M
Median
Jun 2023
Cash from Investing (Quarterly) Benchmarks
| Catalent Inc | -74.00M |
| AIM ImmunoTech Inc | -0.158M |
| Perspective Therapeutics Inc | -47.30M |
| Protalix BioTherapeutics Inc | -0.606M |
| Armata Pharmaceuticals Inc | -0.25M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -22.96M |
| Cash from Financing (Quarterly) | 0.111M |
| Free Cash Flow | -133.45M |
| Free Cash Flow Per Share (Quarterly) | -0.2796 |
| Free Cash Flow to Equity (Quarterly) | -23.15M |
| Free Cash Flow Yield | -105.0% |